Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target of ...
The company’s projected adjusted diluted EPS for 2025 is between $5.05 and $5.25, marking double-digit growth at the midpoint. Abbott’s first-quarter 2025 adjusted EPS is expected to be between $1.05 ...
Abbott Laboratories just extended its dividend growth streak with a 7.3% hike in the quarterly dividend per share last month.
The lawsuit accuses the formula maker of deceptively marketing the milks to make them seem like the next recommended step for toddlers.
For 2025, Abbott forecast organic sales growth of between 7.5% and 8.5%, as well as adjusted earnings per share of $5.05 to $5.25. Analysts expect $5.16 a share on $42 billion in sales.
Abbott Laboratories on Wednesday forecast first-quarter profit below Wall Street estimates, along with weak fourth-quarter ...
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.66% of ...
The organization that filed the proposed class action alleges marketing for the product tricks parents of young children who ...
Seeking Alpha on MSN1d
Abbott Laboratories slips after Q4 topline missAbbott Laboratories (ABT) stock traded lower in the premarket on Wednesday after its Q4 2024 results fell short of Street ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback